Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Noninvasive imaging markers in prostate cancer

AACR 2012

Published: 13 Apr 2012

Views: 3936

Rating:

Save

Dr Michael Evans - Memorial Sloan-Kettering Cancer Center, New York, USA

Dr Evans presents results from a study on the use of a novel, noninvasive imaging tool that allows researchers to measure free prostate-specific antigen in prostate cancer models and to visualise bone metastasis in a tumour-specific manner.

The results were presented at the AACR 2012 Annual meeting in Chicago.

ecancerNews Coverage: Novel technology allows for noninvasive imaging of prostate cancer

Related Videos

To test or not to test? Targeted therapies in GU Cancers – leveraging new...

Prof Eva Compérat, Dr Friederike Schlürmann and Dr Guilhem Roubaud

To test or not to test? Targeted therapies in GU Cancers – leveraging new advances in clinical care ( Prof Eva Compérat, Dr Friederike Schlürmann and Dr Guilhem Roubaud )

Remote genetic testing has the potential to increase the uptake of testing in...

Dr Bruce Montgomery - University of Washington, Seattle, USA

Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems ( Dr Bruce Montgomery - University of Washington, Seattle, USA )

Baseline characteristics of patients with PSMA-PET–positive and –negative...

Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany

Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk BCR after radical RP ( Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany )

A biomarker led approach to bladder cancer

Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...

A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )

Erdafitinib and current treatment landscape for advanced bladder cancer

Dr Yohann Loriot and Prof Arlene Siefker-Radtke

Erdafitinib and current treatment landscape for advanced bladder cancer ( Dr Yohann Loriot and Prof Arlene Siefker-Radtke )

AI-derived digital pathology-based biomarker predicts benefit of long-term ADT...

Prof Andrew Armstrong - Duke University, Durham, USA

AI-derived digital pathology-based biomarker predicts benefit of long-term ADT with RT in localised high-risk prostate cancer ( Prof Andrew Armstrong - Duke University, Durham, USA )

Molecular profiling in prostate cancer: key challenges for clinical...

Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain

Molecular profiling in prostate cancer: key challenges for clinical implementation ( Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain )

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer

Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike...

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer ( Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürmann )

Bladder cancer: Current state and future directions in treatment

Prof Jorge Garcia - GU Medical Oncology Program, UH Seidman Cancer Center, Case...

Bladder cancer: Current state and future directions in treatment ( Prof Jorge Garcia - GU Medical Oncology Program, UH Seidman Cancer Center, Case Western Reserve University, Cleveland, USA )

More from ecancer